

# Leveraging Promotions for Social Good: Insights from COVID-19 Vaccine Distribution

Daniel Gulti Kebede<sup>1</sup>   James Reeder III<sup>2</sup>

<sup>1</sup>School of Management, Department of Economics  
Purdue University

<sup>2</sup>School of Management, Department of Marketing  
Purdue University

Briefing, November 2022

# Overview

- 1 Motivation
- 2 Literature Review
- 3 Data Source
- 4 Identification Strategy Results
- 5 Conclusion

# Motivation

- The role of advertisement in influencing consumers' uptake of private goods and services is well studied
- Promotions can have opposite effect – it can reduce the perceived quality of goods and services
- Promotions range from free tickets to a national park and free beer at a local bar to chance to win a lottery and cash payments

# Motivation



- Why is our set-up novel?
  - Government reacted quickly to boost vaccine uptake
  - Promotions are introduced at the state level
  - exploit heterogeneity at the county level– various policy experiments
- What is the average effect of promotion on vaccine adoption?
- Also explore heterogeneity– across income, race?

- Allan J. Walkey et al (2021): Lottery-Based incentive in Ohio and COVID-19 vaccination rates
- Thiess Buettner (2006): The incentive effect of fiscal equalization transfers on tax policy
- Shuming Ren and Ziyu Song (2020): Intellectual capital and firm innovation: incentive effect and selection
- Maryke et al (2020): Using Social Media for Vaccination Promotion: Practice and Challenges


# Data Source

- We used vaccination data from Centers for Disease Control and Prevention (CDC)
- Further CDC Data: COVID Death Statistics and Vaccine Hesitancy/Health Access Measures at the county-level
- Collected Voting Differential in the 2020 election, county-level
- Demographic Information and Number of Hospitals within the county
- Exploring time-varying social distancing metrics (Safegraph/Apple/Google)

# Breakdown of counties: treated vs control and treatment types



# The average rate of vaccination: treatment vs control counties





# How to recover the causal effect? Common Practice

$$Y_{i,t} = \alpha_i + \lambda_t + \beta^{TWFE} D_{i,t} + \beta X_{i,t} + \epsilon_{i,t} \quad (1)$$

where  $Y_{i,t}$  represents percentage vaccinated in county  $i$  at period  $t$ .

controls	Model 1	Model 2
treatment	1.753*	2.6*
deaths	-.0415*	-0.042*
minority*treatment		-4.97*
constant	0.255	0.258
$\lambda_t$	Yes	Yes
$\alpha_i$	Yes	Yes

# TWFE estimates are biased!

- researchers routinely interpret  $\beta^{TWFE}$  as “a causal parameter of interest”
- States adopted incentives at different periods– the treatments are also heterogeneous
- Two Way Fixed Effect (TWFE) might result in under-identification and spurious identification of long-run treatments

# There must be a better way?

## Reduced Form Model

Difference-in-Differences (DiD) with staggered treatment adoption and variation in treatment timing (Borusyak, Jaravel and Spiess (2021), Callaway and Sant'Anna (2020), Sun and Abraham (2020), de Chaisemartin and D'Haultfoeuille(2017))

## Structural Form Model

Estimate utility-based Diffusion Model (Cosguner and Seetharaman (2022))

# Reduced Form: Treatment grouping-based estimation

Here we explain the method by Callaway and Sant'Anna (hereafter CS(2020)). They consider identification and inference with:

- multiple time periods
- variation in treatment timing, and
- when the "parallel trends assumption" holds potentially only after conditioning on observed covariates

# Reduced Form: Treatment grouping-based estimation

We are interested in the causal effect:

$$ATT(g, t) = \mathbb{E}[Y_t(g) - Y_t(0) | G_g = 1] \quad \text{for } t \geq g \quad (2)$$

Taking weighted average of the  $ATT(g, t)$ :


$$\tau_{CS} = \sum_{g=2}^K \sum_{t=2}^T \mathbb{1}(g \leq t) \omega_{gt} ATT(g, t) \quad (3)$$

## Reduced Form: Treatment grouping-based estimation

	coefficient	std. err.	z
$\tau_{CS}$	0.74	.21	3.57**

The causal effect of incentives on vaccine uptake is 0.74 %. This is the weighted average treatment on the treated (ATT) estimate.

# Event study plots: Grouping Based Results



# No more identification threat?

Does the latest DiD address all identification concerns? Not exactly!

- One potential identification threat is self-selection into treatment (at State level)
- Solution: estimate a structural model!
  - For the treatment counties we estimate the vaccine diffusion pattern when they are in and out of treatment
  - We use Random Forest to build the counterfactual (i.e. out of treatment diffusion pattern) using the features of non-treated counties



# Structural Model: Bass Diffusion Model

- Given a market size of  $M$  consumers for a new product, the likelihood that a consumer will adopt a new product at time  $t$ , given that the consumer has not yet adopted, is given by:

$$\frac{f(t)}{1 - F(t)} = p + qF(t) \quad (4)$$

where  $p$  and  $q$  represents the coefficients of innovation and imitation, respectively.  $F(t)$  is cumulative distribution function and  $f(t)$  is the probability density function.

# Structural Model: Bass Diffusion Model

- Assuming  $F(0) = 0$  and solving the differential equation (4), we get:

$$F(t) = \frac{1 - e^{-(p+q)t}}{1 + \frac{q}{p}e^{-(p+q)t}} \quad (5)$$

- Given  $N(t)$ , the observed vaccine data, the predicted vaccination is given by:

$$N(\hat{t}) = M[F(t) - F(t - 1)] \quad (6)$$

# Structural Model: Deriving Bass Model as a Utility-Based Diffusion Model

- Given a market size of  $M$  consumers, assume the utility of a consumer for the new product at time  $t$  is given by:

$$U_t = \ln \left[ \ln \left[ \frac{1 - F(t-1)}{1 - F(t)} \right] \right] + \mathbf{X}_t \boldsymbol{\beta} + \epsilon_t \quad (7)$$

where  $\epsilon_t$  follows a logistic distribution with location parameter 0 and scale parameter 1.

# Structural Model: Deriving Bass Model as a Utility-Based Diffusion Model

- Now, the discrete hazard function characterizing the consumer's time to adoption for the new product is given by:

$$pr_t = \frac{e^{w_t}}{1 + e^{w_t}} \quad (8)$$

where

$$w_t = \ln \left[ \ln \left[ \frac{1 - F(t-1)}{1 - F(t)} \right] \right] + \mathbf{X}_t \beta$$

- The consumer's unconditional likelihood of buying the new product at time  $t$  will be:

$$L_t = \left[ \prod_{s=1}^{t-1} 1 - pr(s) \right] pr(t) \quad (9)$$

# Structural Model: Constructing Counterfactual

- We use Random Forest to predict the diffusion parameters  $p$ ,  $q$  and  $m$  for the treated counties based on untreated counties
- Nonparametric approach
- Similar to synthetic controls
- We compare the vaccine diffusion for treated counties against the respective counterfactual


# Structural Model: Deriving Bass Model as a Utility-Based Diffusion Model

- The probability of vaccine adoption in and out of treatment will be given by  $p$  and  $\hat{p}$ , respectively
- Treatment effect on contemporaneous correlation will be given by the difference in the log odds ratios

$$\tau = \log\left(\frac{p}{1-p}\right) - \log\left(\frac{\hat{p}}{1-\hat{p}}\right) \quad (10)$$

- To measure heterogeneity, the treatment effects will be projected onto covariates

# Bass Treatment Effects— median $\tau = -0.5948$



# Bass Treatment Effects– exploring heterogeneity!

$$\tau_i^{bass} = \beta_0 + \beta_1 novax_i + \beta_2 vote_i + \beta_3 income_i + \epsilon_i \quad (11)$$

where  $vote = \text{Trump's vote share} - \text{Biden's vote share}$

treatment effect	Coefficient	std. err.	t-stat
constant	-0.629	0.172	-3.65***
vaccine hesitant	-5.13	0.811	-6.33***
vote	-0.217	0.095	-2.27**
log(income)	0.094	0.022	4.19***

‡ We used bootstrap standard errors.



# Conclusion

- careful about the adverse effects of promotion on public good consumption
- estimates from the reduced form model differs from the Bass diffusion model results
- vaccine hesitant became more hesitant
- red states became more hesitant